secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001104659-26-057460
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data
--------------------------------------------------------------------------------

- Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.
- Phase 2b CLOVER WaM: 83.6% ORR, 61.8% MRR, median DoR 17.8 months in r/r WM.
- BTKi-exposed: 64.1% MRR, median PFS 15.9 mo; BTKi-refractory: 63.6% MRR, median PFS 14.8 mo.
- Nantahala gets board seat; warrants exercisable upon stockholder approval at $2.65.
- Proceeds to support Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/tm2613728d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-057460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer